Access the full text.
Sign up today, get DeepDyve free for 14 days.
Yong‐Fu Xiao, Q. Ke, Yu Chen, J. Morgan, A. Leaf (2004)
Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells.Biochemical and biophysical research communications, 321 1
Xiaoming Jia, P. Kohli, S. Virani (2019)
Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical TrialsCurrent Atherosclerosis Reports, 21
A. Abdelhamid, T. Brown, J. Brainard, Priti Biswas, G. Thorpe, H. Moore, K. Deane, Fai AlAbdulghafoor, C. Summerbell, H. Worthington, F. Song, L. Hooper (2018)
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews, 7
Ž. Reiner (2017)
Hypertriglyceridaemia and risk of coronary artery diseaseNature Reviews Cardiology, 14
S. Baum, K. Scholz (2019)
Rounding the corner on residual risk: Implications of REDUCE‐IT for omega‐3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular diseaseClinical Cardiology, 42
A. König, Colleen Bouzan, Joshua Cohen, W. Connor, P. Kris-Etherton, G. Gray, R. Lawrence, D. Savitz, S. Teutsch (2005)
A quantitative analysis of fish consumption and coronary heart disease mortality.American journal of preventive medicine, 29 4
Cheng-Ho Chang, P. Tseng, N. Chen, Pei-Chin Lin, Pao-Yen Lin, J. Chang, F. Kuo, Jenshinn Lin, Ming‐Chang Wu, K. Su (2018)
Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials.Prostaglandins, leukotrienes, and essential fatty acids, 129
Deepak Bhatt, P. Steg, Michael Miller, E. Brinton, T. Jacobson, S. Ketchum, R. Doyle, R. Juliano, L. Jiao, C. Granowitz, J. Tardif, J. Gregson, S. Pocock, C. Ballantyne (2019)
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.Journal of the American College of Cardiology, 73 22
P. Pérez-Martínez, N. Katsiki, D. Mikhailidis (2020)
The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the FutureAngiology, 71
J. Manson, N. Cook, I. Lee, W. Christen, S. Bassuk, S. Mora, Heike Gibson, C. Albert, D. Gordon, T. Copeland, Denise D’Agostino, G. Friedenberg, C. Ridge, V. Bubes, E. Giovannucci, W. Willett, J. Buring (2019)
Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and CancerThe New England Journal of Medicine, 380
Y. Nishizaki, K. Shimada, H. Daida (2017)
The balance of omega-3 polyunsaturated fatty acids for -reducing residual risks in patients with coronary artery diseaseActa Cardiologica, 72
Esther Kim, P. McCormack (2014)
Icosapent Ethyl: A Review of Its Use in Severe HypertriglyceridemiaAmerican Journal of Cardiovascular Drugs, 14
A. Hirai, T. Terano, H. Saito, Y. Tamura, S. Yoshida (1984)
EICOSAPENTAENOIC ACID AND PLATELET FUNCTION IN JAPANESE
M. Budoff, J. Muhlestein, V. Le, H. May, Sion Roy, J. Nelson (2018)
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE studyClinical Cardiology, 41
C. Ballantyne, H. Bays, Sephy Philip, R. Doyle, R. Braeckman, W. Stirtan, Paresh Soni, R. Juliano (2016)
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.Atherosclerosis, 253
Deepak Bhatt, P. Steg, Michael Miller, E. Brinton, T. Jacobson, S. Ketchum, R. Doyle, R. Juliano, L. Jiao, C. Granowitz, J. Tardif, C. Ballantyne (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaThe New England Journal of Medicine, 380
ML Burr, P. Ashfield-Watt, F. Dunstan, A. Fehily, P. Breay, T. Ashton, PC Zotos, Naa Haboubi, P. Elwood (2003)
Lack of benefit of dietary advice to men with angina: results of a controlled trialEuropean Journal of Clinical Nutrition, 57
W. Harris (2019)
Understanding why REDUCE-IT was positive - Mechanistic overview of eicosapentaenoic acid.Progress in cardiovascular diseases
(2019)
FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groupsCase Medical Research
Yang Hu, F. Hu, J. Manson (2019)
Marine Omega‐3 Supplementation and Cardiovascular Disease: An Updated Meta‐Analysis of 13 Randomized Controlled Trials Involving 127 477 ParticipantsJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 8
P. Kowey, J. Reiffel, K. Ellenbogen, G. Naccarelli, C. Pratt (2010)
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.JAMA, 304 21
B. Karlson, M. Palmer, S. Nicholls, P. Lundman, P. Barter (2016)
A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.The American journal of cardiology, 117 9
C. Orringer (2020)
Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?Trends in cardiovascular medicine
Xiaoming Jia, Stephanie Koh, M. Rifai, R. Blumenthal, S. Virani (2020)
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to DateVascular Health and Risk Management, 16
H. Bucher, P. Hengstler, C. Schindler, G. Meier (2002)
N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.The American journal of medicine, 112 4
O. Sheikh, Anthony Hei, Ayman Battisha, T. Hammad, S. Pham, R. Chilton (2019)
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trialCardiovascular Diabetology, 18
B. Rauch, R. Schiele, S. Schneider, Frank Diller, N. Victor, H. Gohlke, M. Gottwik, G. Steinbeck, Ulrike Castillo, Rudolf Sack, Heinrich Worth, H. Katus, W. Spitzer, G. Sabin, J. Senges (2010)
OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial InfarctionCirculation, 122
C. Ballantyne, H. Bays, R. Braeckman, Sephy Philip, W. Stirtan, R. Doyle, Paresh Soni, R. Juliano (2014)
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.Journal of clinical lipidology, 10 3
F. Mach, C. Baigent, A. Catapano, K. Koskinas, M. Casula, L. Badimón, M. Chapman, G. Backer, V. Delgado, B. Ference, I. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T. Pedersen, G. Riccardi, D. Richter, M. Sabatine, M. Taskinen, L. Tokgozoglu, O. Wiklund, S. Windecker, V. Aboyans, J. Collet, V. Dean, D. Fitzsimons, C. Gale, D. Grobbee, S. Halvorsen, G. Hindricks, B. Iung, P. Jüni, H. Katus, C. Leclercq, M. Lettino, B. Lewis, B. Merkely, Christian Mueller, Steffen Petersen, A. Petronio, M. Roffi, E. Shlyakhto, I. Simpson, M. Sousa‐Uva, R. Touyz, D. Nibouche, P. Zelveian, P. Siostrzonek, R. Najafov, P. Borne, B. Pojskić, A. Postadzhiyan, Lambros Kypris, J. Špinar, M. Larsen, H. Eldin, M. Viigimaa, T. Strandberg, J. Ferrières, R. Agladze, U. Laufs, L. Rallidis, L. Bajnok, T. Gudjonsson, V. Maher, Y. Henkin, M. Gulizia, A. Mussagaliyeva, Gani Bajraktari, A. Kerimkulova, G. Latkovskis, O. Hamoui, R. Šlapikas, Laurent Visser, P. Dingli, V. Ivanov, A. Bošković, M. Nazzi, F. Visseren, I. Mitevska, K. Retterstøl, P. Jankowski, R. Fontes-Carvalho, D. Gaita, M. Ezhov, M. Foscoli, V. Giga, D. Pella, Z. Fras, L. Isla, E. Hagström, R. Lehmann, L. Abid, O. Ozdogan, O. Mitchenko, R. Patel (2019)
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.Atherosclerosis
Evan O’Keefe, W. Harris, J. DiNicolantonio, A. Elagizi, R. Milani, C. Lavie, J. O’Keefe (2019)
Sea Change for Marine Omega-3s: Randomized Trials Show Fish Oil Reduces Cardiovascular Events.Mayo Clinic proceedings
L. Bowman, M. Mafham, K. Wallendszus, W. Stevens, G. Buck, J. Barton, K. Murphy, Theingi Aung, R. Haynes, J. Cox, A. Murawska, A. Young, M. Lay, Fang Chen, E. Sammons, E. Waters, A. Adler, J. Bodansky, A. Farmer, R. Mcpherson, A. Neil, D. Simpson, R. Peto, C. Baigent, R. Collins, S. Parish, J. Armitage (2018)
Effects of n‐3 Fatty Acid Supplements in Diabetes MellitusThe New England Journal of Medicine, 379
R. Mason (2019)
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular DiseaseCurrent Atherosclerosis Reports, 21
V. Bittner (2019)
Implications for REDUCE IT in clinical practice.Progress in cardiovascular diseases
M. Bäck, G. Hansson (2019)
Omega‐3 fatty acids, cardiovascular risk, and the resolution of inflammationThe FASEB Journal, 33
Ramyashree Tummala, R. Ghosh, Vardhmaan Jain, A. Devanabanda, D. Bandyopadhay, P. Deedwania, W. Aronow (2019)
Fish Oil And Cardiometabolic Diseases: Recent Updates And Controversies.The American journal of medicine
S. Kwak, S. Myung, Young Lee, H. Seo (2012)
Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.Archives of internal medicine, 172 9
(2014)
Writing Group for the AREDS2
H. Bays, C. Ballantyne, J. Kastelein, J. Isaacsohn, R. Braeckman, Paresh Soni (2011)
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).The American journal of cardiology, 108 5
Gissi-Prevenzione Investigators (1999)
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trialThe Lancet, 354
T. Jacobson (2014)
Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemiaClinical Lipidology, 9
P. Galan, E. Kesse‐Guyot, S. Czernichow, S. Briançon, J. Blacher, S. Hercberg (2010)
Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trialThe BMJ, 341
C. Orringer, T. Jacobson, K. Maki (2019)
National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.Journal of clinical lipidology
A. Sakamoto, M. Saotome, Keisuke Iguchi, Yuichiro Maekawa (2019)
Marine-Derived Omega-3 Polyunsaturated Fatty Acids and Heart Failure: Current Understanding for Basic to Clinical RelevanceInternational Journal of Molecular Sciences, 20
Y. Saito, M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura, T. Kita, A. Kitabatake, N. Nakaya, T. Sakata, K. Shimada, K. Shirato (2008)
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).Atherosclerosis, 200 1
(2018)
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019Diabetes Care, 42
D. Hilleman, B. Wiggins, M. Bottorff (2020)
Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative ReviewAdvances in Therapy, 37
M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Saito, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura, T. Kita, A. Kitabatake, N. Nakaya, T. Sakata, K. Shimada, K. Shirato (2007)
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysisThe Lancet, 369
Colleen Bouzan, Joshua Cohen, W. Connor, P. Kris-Etherton, G. Gray, A. König, R. Lawrence, D. Savitz, S. Teutsch (2005)
A quantitative analysis of fish consumption and stroke risk.American journal of preventive medicine, 29 4
J. Fialkow (2016)
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription ProductsAmerican Journal of Cardiovascular Drugs, 16
J. Donadio, T. Larson, E. Bergstralh, J. Grande (2001)
A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy.Journal of the American Society of Nephrology : JASN, 12 4
E. Rizos, E. Ntzani, E. Bika, M. Kostapanos, M. Elisaf (2012)
Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.JAMA, 308 10
P. Kris-Etherton, Chesney Richter, K. Bowen, Ann Skulas-Ray, K. Jackson, K. Petersen, W. Harris (2019)
Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.Methodist DeBakey cardiovascular journal, 15 3
H. Grimm, N. Mertes, C. Goeters, E. Schlotzer, K. Mayer, F. Grimminger, P. Fürst (2006)
Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patientsEuropean Journal of Nutrition, 45
G. Einvik, Tor Klemsdal, L. Sandvik, E. Hjerkinn (2010)
A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular riskEuropean Journal of Preventive Cardiology, 17
Y. Nishizaki, K. Shimada, S. Tani, Takayuki Ogawa, Jiro Ando, Masao Takahashi, Masato Yamamoto, T. Shinozaki, K. Miyauchi, K. Nagao, A. Hirayama, M. Yoshimura, I. Komuro, R. Nagai, H. Daida (2014)
Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome.The American journal of cardiology, 113 3
F. Picard, Deepak Bhatt, G. Ducrocq, Y. Elbez, R. Ferrari, I. Ford, J. Tardif, M. Tendera, K. Fox, P. Steg (2019)
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease.Journal of the American College of Cardiology, 73 11
Gissi-Hf Investigators (2008)
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 372
Ann Skulas-Ray, P. Wilson, W. Harris, E. Brinton, P. Kris-Etherton, Chesney Richter, T. Jacobson, M. Engler, Michael Miller, Jennifer Robinson, C. Blum, D. Rodriguez-Leyva, S. Ferranti, F. Welty (2019)
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.Circulation
S. Doggrell (2019)
Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemiaExpert Opinion on Pharmacotherapy, 20
Independent Data Monitoring Committee has recommended to discontinue the trial as Epanova is unlikely to demonstrate a benefit to patients (AstraZeneca press release dated
P. Calder (2017)
Omega-3 fatty acids and inflammatory processes: from molecules to man.Biochemical Society transactions, 45 5
A. Hirai, T. Hamazaki, T. Terano, T. Nishikawa, Y. Tamura, A. Kumagai, J. Sajiki (1980)
EICOSAPENTAENOIC ACID AND PLATELET FUNCTION IN TAPANESEThe Lancet, 316
D. Bandyopadhyay, A. Qureshi, Sudeshna Ghosh, K. Ashish, Lyndsey Heise, A. Hajra, R. Ghosh (2018)
Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia ManagementJournal of Lipids, 2018
D. Bonds, M. Harrington, B. Worrall, A. Bertoni, C. Eaton, J. Hsia, Jennifer Robinson, T. Clemons, Lawrence Fine, E. Chew (2014)
Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.JAMA internal medicine, 174 5
M. Roncaglioni, Massimo Tombesi, F. Avanzini, S. Barlera, V. Caimi, P. Longoni, I. Marzona, V. Milani, M. Silletta, G. Tognoni, R. Marchioli (2013)
n-3 fatty acids in patients with multiple cardiovascular risk factors.The New England journal of medicine, 368 19
D. Kromhout, E. Giltay, J. Geleijnse (2010)
n-3 fatty acids and cardiovascular events after myocardial infarction.The New England journal of medicine, 363 21
C. Schacky (2018)
Rebuttal to Aung et al, "Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals".Alternative therapies in health and medicine, 24 2
(2020)
ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular RiskDigital Doctor
J. Bosch, H. Gerstein, G. Dagenais, R. Diaz, L. Dyal, Hyejung Jung, Aldo Maggiono, J. Probstfield, Ambady Ramachandran, M. Riddle, L. Rydén, S. Yusuf (2012)
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.The New England journal of medicine, 367 4
P. Swann, D. Venton, G. Breton (1989)
Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A2/prostaglandin H2 receptor in human plateletsFEBS Letters, 243
T. Domei, H. Yokoi, S. Kuramitsu, Y. Soga, T. Arita, K. Ando, S. Shirai, Katsuhiro Kondo, Koyu Sakai, M. Goya, M. Iwabuchi, M. Ueeda, M. Nobuyoshi (2012)
Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention.Circulation journal : official journal of the Japanese Circulation Society, 76 2
F. Mach, C. Baigent, A. Catapano, Konstantinos Koskinas, M. Casula, Lina Badimon, M. Chapman, Guy Backer, V. Delgado, B. Ference, Ian Graham, A. Halliday, Ulf Landmesser, B. Mihaylova, T. Pedersen, G. Riccardi, D. Richter, M. Sabatine, M. Taskinen, L. Tokgozoglu, Olov Wiklund, Christian Mueller, H. Drexel, V. Aboyans, Alberto Corsini, W. Doehner, M. Farnier, B. Gigante, M. Kayıkçıoğlu, G. Krstačić, E. Lambrinou, Basil Lewis, Joseph Masip, P. Moulin, Steffen Petersen, A. Petronio, M. Piepoli, Xavier Pintó, L. Räber, K. Ray, Željko Reiner, Walter Riesen, M. Roffi, J. Schmid, E. Shlyakhto, Iain Simpson, E. Stroes, I. Sudano, A. Tselepis, M. Viigimaa, C. Vindis, A. Vonbank, M. Vrablík, Mislav Vrsalović, J. Zamorano, Jean-Philippe Collet, M. Chapman, Stephan Windecker, V. Dean, Donna Fitzsimons, C. Gale, D. Grobbee, S. Halvorsen, Gerhard Hindricks, Bernard Iung, P. Jüni, H. Katus, Christophe Leclercq, M. Lettino, B. Merkely, M. Sousa‐Uva, R. Touyz, D. Nibouche, P. Zelveian, P. Siostrzonek, R. Najafov, P. Borne, B. Pojskić, A. Postadzhiyan, Lambros Kypris, J. Špinar, M. Larsen, H. Eldin, Timo Strandberg, J. Ferrières, R. Agladze, U. Laufs, L. Rallidis, L. Bajnok, T. Gudjonsson, Vincent Maher, Y. Henkin, M. Gulizia, A. Mussagaliyeva, Gani Bajraktari, A. Kerimkulova, G. Latkovskis, O. Hamoui, R. Šlapikas, Laurent Visser, P. Dingli, V. Ivanov, A. Bošković, M. Nazzi, F. Visseren, I. Mitevska, K. Retterstøl, P. Jankowski, Ricardo Fontes-Carvalho, D. Gaita, M. Ezhov, M. Foscoli, V. Giga, D. Pella, Z. Fras, L. Isla, E. Hagström, R. Lehmann, L. Abid, O. Ozdogan, O. Mitchenko, Riyaz Patel (2019)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.European heart journal
The health benefit of fish oil, i.e. omega-3 fatty acids (ω-3 FA) has a long history of debate. While there are a number of medications to reduce serum triglyceride levels, none have shown unanimous cardiovascular (CV) benefits. The most recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) assessing the CV outcome of one highly purified prescription ω-3 FA has certainly rejuvenated the debate. While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Mar 11, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.